

Dan Atar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7905728/publications.pdf>

Version: 2024-02-01

272
papers

56,360
citations

20817
60
h-index

1072
233
g-index

291
all docs

291
docs citations

291
times ranked

43477
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis. <i>Clinical Research in Cardiology</i> , 2022, 111, 428-439.	3.3	22
2	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 227-235.	3.0	6
3	Performance of the European Society of Cardiology 0/1-Hour, 0/2-Hour, and 0/3-Hour Algorithms for Rapid Triage of Acute Myocardial Infarction. <i>Annals of Internal Medicine</i> , 2022, 175, 101-113.	3.9	37
4	The Role of ECG in the Diagnosis and Risk Stratification of Acute Coronary Syndromes: an Old but Indispensable Tool. <i>Current Cardiology Reports</i> , 2022, 24, 109-118.	2.9	4
5	Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS&ADONIS trials. <i>Clinical Cardiology</i> , 2022, 45, 101-109.	1.8	1
6	The Association of Smoking with Hospitalization and Mortality Differs According to Sex in Patients with Heart Failure Following Myocardial Infarction. <i>Journal of Women's Health</i> , 2022, 31, 310-320.	3.3	2
7	Cost-Minimization Analysis for Cardiac Revascularization in 12 Health Care Systems Based on the EuroCMR/SPINS Registries. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 607-625.	5.3	15
8	Cryptogenic stroke and TIA: Suggested diagnostic approach while waiting for evaluation and treatment guidelines. <i>Acta Neurologica Scandinavica</i> , 2022, 145, 641-646.	2.1	4
9	Do We Really Need Aspirin Loading for STEMI?. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 1221-1238.	2.6	7
10	Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 782-790.	7.1	16
11	Performance of the Novel Observation Group Criteria of the European Society of Cardiology (ESC) 0/1&Hour Algorithm in a Low&Risk Population. <i>Journal of the American Heart Association</i> , 2022, 11, e024927.	3.7	2
12	No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab. <i>PLoS ONE</i> , 2022, 17, e0266615.	2.5	5
13	Cardiovascular phenotype of long&term anabolic&androgenic steroid abusers compared with strength&trained athletes. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2022, 32, 1170-1181.	2.9	8
14	Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances. <i>Kardiologia Polska</i> , 2022, 80, 741-749.	0.6	2
15	Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. <i>Heart Failure Reviews</i> , 2021, 26, 1421-1435.	3.9	26
16	GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke. <i>Future Cardiology</i> , 2021, 17, 19-38.	1.2	19
17	Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): Rationale and design. <i>American Heart Journal</i> , 2021, 231, 96-104.	2.7	49
18	The perils of data sharing, meta-analyses, and estimating cardiovascular risk. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e55-e57.	3.0	0

#	ARTICLE	IF	CITATIONS
19	Efficacy of Long-Term Oral Beta-Blocker Therapy in Patients Who Underwent Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction With Preserved Left Ventricular Ejection Fraction: A Systematic Review and Meta-analysis. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 87-93.	1.9	4
20	Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation – results from the GARFIELD-AF registry. <i>Annals of Medicine</i> , 2021, 53, 485-494.	3.8	0
21	Use of Non-vitamin K Antagonist Oral Anticoagulants for Stroke Prevention across the Stroke Spectrum: Progress and Prospects. <i>Thrombosis and Haemostasis</i> , 2021, 121, 716-730.	3.4	2
22	New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?. <i>Atherosclerosis</i> , 2021, 319, 51-61.	0.8	37
23	Comparison of a single high-sensitivity cardiac troponin T measurement with the HEART score for rapid rule-out of acute myocardial infarction in a primary care emergency setting: a cohort study. <i>BMJ Open</i> , 2021, 11, e046024.	1.9	8
24	Is RBBB the new LBBB? Are we going to repeat the same mistakes?. <i>Journal of Electrocardiology</i> , 2021, 65, 34-36.	0.9	3
25	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , 2021, 23, 1612-1676.	1.7	494
26	The Times They Are A-Changin': Antithrombotic strategies in patients with acute coronary syndrome undergoing coronary stenting who have concomitant atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2021, 88, 21-22.	2.2	1
27	Modulating the Intensity of Oral Anticoagulation Therapy with Direct Oral Anticoagulants: Feasible or Not?. <i>American Journal of Cardiovascular Drugs</i> , 2021, , 1.	2.2	1
28	Icons in Cardiology. <i>Cardiology</i> , 2021, 146, 667.	1.4	0
29	The debated issue of direct oral anticoagulants correct dosing: When even the reviewer is confused. <i>European Journal of Internal Medicine</i> , 2021, 90, 125-126.	2.2	0
30	Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data. <i>BMJ, The</i> , 2021, 375, e066450.	6.0	6
31	Diagnostic Accuracy and Usability of the ECG247 Smart Heart Sensor Compared to Conventional Holter Technology. <i>Journal of Healthcare Engineering</i> , 2021, 2021, 1-8.	1.9	9
32	MVnet: automated time-resolved tracking of the mitral valve plane in CMR long-axis cine images with residual neural networks: a multi-center, multi-vendor study. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2021, 23, 137.	3.3	6
33	Characteristics, treatment patterns, and residual cardiovascular risk of patients with a first acute myocardial infarction: A nationwide population-based cohort study in Norway. <i>Fundamental and Clinical Pharmacology</i> , 2021, , .	1.9	0
34	Does Ivabradine Decrease Cardiovascular Deaths in Heart Failure Patients?. <i>American Journal of Medicine</i> , 2020, 133, 347-351.	1.5	2
35	Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 86-93.	3.0	27
36	The myth of "stable" coronary artery disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 9-21.	13.7	89

#	ARTICLE	IF	CITATIONS
37	Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials. Heart Failure Reviews, 2020, 25, 161-171.	3.9	8
38	The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events. Europace, 2020, 22, 195-204.	1.7	22
39	Pre-hospital One-Hour Troponin in a Low-Prevalence Population of Acute Coronary Syndrome: OUT-ACS study. Open Heart, 2020, 7, e001296.	2.3	8
40	Inferior ST-Elevation Myocardial Infarction Presenting When Urgent Primary Percutaneous Coronary Intervention Is Unavailable: Should We Adhere to Current Guidelines?. Cardiovascular Drugs and Therapy, 2020, 34, 865-870.	2.6	4
41	ESC Core Curriculum for the Cardiologist. European Heart Journal, 2020, 41, 3605-3692.	2.2	38
42	The cancer patient and cardiology. European Journal of Heart Failure, 2020, 22, 2290-2309.	7.1	62
43	Cardioversion Safety “Are We Doing Enough?. Cardiology, 2020, 145, 740-745.	1.4	1
44	Prevalence of genetically verified familial hypercholesterolemia among young (<45 years) Norwegian patients hospitalized with acute myocardial infarction. Journal of Clinical Lipidology, 2020, 14, 339-345.	1.5	7
45	Worst lead ST deviation and resolution of ST elevation at one hour for prediction of myocardial salvage, infarct size, and microvascular obstruction in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Annals of Noninvasive Electrocardiology, 2020, 25, e12784.	1.1	3
46	Biomarkers Associated with Atrial Fibrillation in Patients with Ischemic Stroke: A Pilot Study from the NOR-FIB Study. Cerebrovascular Diseases Extra, 2020, 10, 11-20.	1.5	9
47	Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial. Trials, 2020, 21, 415.	1.6	21
48	Self-Care Monitoring of Heart Failure Symptoms and Lung Impedance at Home Following Hospital Discharge: Longitudinal Study. Journal of Medical Internet Research, 2020, 22, e15445.	4.3	15
49	Fourth universal definition of myocardial infarction (2018). European Heart Journal, 2019, 40, 237-269.	2.2	2,687
50	Pathophysiology, Diagnosis, and Management of the No-Reflow Phenomenon. Cardiovascular Drugs and Therapy, 2019, 33, 589-597.	2.6	44
51	Heat Stress Impacts on Cardiac Mortality in Nepali Migrant Workers in Qatar. Cardiology, 2019, 143, 37-48.	1.4	58
52	Challenging Anticoagulation in Advanced Renal Failure. American Journal of Medicine, 2019, 132, 1258-1259.	1.5	3
53	Gender but not diabetes, hypertension or smoking affects infarct evolution in ST-elevation myocardial infarction patients “data from the CHILL-MI, MITOCARE and SOCCER trials. BMC Cardiovascular Disorders, 2019, 19, 161.	1.7	5
54	Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF. American Journal of Medicine, 2019, 132, 1431-1440.e7.	1.5	8

#	ARTICLE	IF	CITATIONS
55	Angiotensin receptor neprilysin inhibition for the treatment of hypertension: the neglected child in cardiovascular pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 122-123.	3.0	2
56	Gender differences in association between uric acid and all-cause mortality in patients with chronic heart failure. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 4.	1.7	15
57	Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure â€” A multicenter propensity score matched analysis. <i>International Journal of Cardiology</i> , 2019, 289, 83-90.	1.7	10
58	Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 171-180.	3.0	46
59	Atrial fibrillation in cryptogenic stroke and transient ischaemic attack â€” The Nordic Atrial Fibrillation and Stroke (NOR-FIB) Study: Rationale and design. <i>European Stroke Journal</i> , 2019, 4, 172-180.	5.5	11
60	Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction. <i>American Heart Journal</i> , 2019, 215, 83-90.	2.7	7
61	Editorâ€™s Note. <i>Cardiology</i> , 2019, 142, 1-1.	1.4	0
62	B-type natriuretic peptide trumps other prognostic markers in patients assessed for coronary disease. <i>BMC Medicine</i> , 2019, 17, 72.	5.5	14
63	Epidemiology and long-term outcome in outpatients with chronic heart failure in Northwestern Europe. <i>Heart</i> , 2019, 105, 1252-1259.	2.9	18
64	Management and 1â€”Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELDâ€”AF Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e010510.	3.7	44
65	On-label reduced doses of non-vitamin K anticoagulants prove safe and efficient; yet how to ensure the correct dose for the right patient?. <i>European Heart Journal</i> , 2019, 40, 1501-1503.	2.2	4
66	Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. <i>Circulation</i> , 2019, 139, 2292-2300.	1.6	78
67	Atrial Fibrillation and Stroke in Patients with Hypertrophic Cardiomyopathy: Important New Insights. <i>Thrombosis and Haemostasis</i> , 2019, 119, 355-357.	3.4	12
68	Ivabradine for heart failure: regulatory differences in Europe and United States. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 119-121.	3.0	0
69	All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System. <i>American Journal of Therapeutics</i> , 2019, 26, e671-e678.	0.9	6
70	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 142	7.1	65
71	Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 210-215.	3.0	7
72	Do We Need Potent Intravenous Antiplatelet Inhibition at the Time of Reperfusion During ST-Segment Elevation Myocardial Infarction?. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 215-224.	2.0	9

#	ARTICLE	IF	CITATIONS
73	BETablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study. American Heart Journal, 2019, 208, 37-46.	2.7	20
74	Health Care Professionals'™ Perceptions of Home Telemonitoring in Heart Failure Care: Cross-Sectional Survey. Journal of Medical Internet Research, 2019, 21, e10362.	4.3	35
75	The heart failure burden of type 2 diabetes mellitus" a review of pathophysiology and interventions. Heart Failure Reviews, 2018, 23, 303-323.	3.9	41
76	Correlation of anteroseptal ST elevation with myocardial infarction territories through cardiovascular magnetic resonance imaging. Journal of Electrocardiology, 2018, 51, 563-568.	0.9	4
77	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. European Heart Journal, 2018, 39, 464-473.	2.2	28
78	European Society of Cardiology: Cardiovascular Disease Statistics 2017. European Heart Journal, 2018, 39, 508-579.	2.2	595
79	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. Europace, 2018, 20, 395-407.	1.7	95
80	How does the TRS 2Â°P score relate to real-world patients?. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 72-74.	3.0	5
81	Longitudinal left ventricular function is globally depressed within a week of <scp>STEMI</scp>. Clinical Physiology and Functional Imaging, 2018, 38, 1029-1037.	1.2	9
82	Correlation of ST changes in leads V4&V6 to area of ischemia by CMR in inferior STEMI. Scandinavian Cardiovascular Journal, 2018, 52, 189-195.	1.2	2
83	Mechanisms of action and clinical use of specific reversal agents for non-vitamin K antagonist oral anticoagulants. Scandinavian Cardiovascular Journal, 2018, 52, 156-162.	1.2	7
84	Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 82-92.	3.0	11
85	Appropriateness of anteroseptal myocardial infarction nomenclature evaluated by late gadolinium enhancement cardiovascular magnetic resonance imaging. Journal of Electrocardiology, 2018, 51, 218-223.	0.9	2
86	Type 2 Diabetes and Heart Failure - More Scrutiny Wanted!. Cardiology, 2018, 139, 37-39.	1.4	1
87	Electrocardiographic scores of severity and acuteness of myocardial ischemia predict myocardial salvage in patients with anterior ST-segment elevation myocardial infarction. Journal of Electrocardiology, 2018, 51, 195-202.	0.9	6
88	Cardiac Magnetic Resonance Evaluation of the Extent of Myocardial Injury in Patients with Inferior ST Elevation Myocardial Infarction and Concomitant ST Depression in Leads V1&V3: Analysis from the MITOCARE Study. Cardiology, 2018, 140, 178-185.	1.4	6
89	Author's response to: letter to the editor. Heart Failure Reviews, 2018, 23, 819-819.	3.9	0
90	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart Journal, 2018, 70, 828-835.	0.5	16

#	ARTICLE	IF	CITATIONS
91	Peripheral arterial disease and limb salvage: a new arena for the cardiologist. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 136-137.	3.0	0
92	Relationship between left ventricular ejection fraction and mortality after myocardial infarction complicated by heart failure or left ventricular dysfunction. <i>International Journal of Cardiology</i> , 2018, 272, 260-266.	1.7	24
93	The significance of ST-segment elevation in aVL in anterolateral myocardial infarction: An assessment by cardiac magnetic resonance imaging. <i>Annals of Noninvasive Electrocardiology</i> , 2018, 23, e12580.	1.1	7
94	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004962.	3.9	117
95	In Current Clinical Practice, after Percutaneous Coronary Intervention for Acute Myocardial Infarction, Are Î²-Blockers Prescribed for Heart Failure or as Secondary Prevention? A Pilot Study. <i>Cardiology</i> , 2018, 140, 152-154.	1.4	3
96	Response to the editor. <i>Heart Failure Reviews</i> , 2018, 23, 819.	3.9	0
97	Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017, 38, ehv676.	2.2	48
98	ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. <i>European Heart Journal</i> , 2017, 38, ehw149.	2.2	511
99	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. <i>European Heart Journal</i> , 2017, 38, ehw069.	2.2	106
100	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. <i>Heart</i> , 2017, 103, 307-314.	2.9	205
101	Spironolactone Treatment and Effect on Survival in Chronic Heart Failure Patients with Reduced Renal Function: A Propensity-Matched Study. <i>CardioRenal Medicine</i> , 2017, 7, 128-136.	1.9	7
102	Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure. <i>Clinical Research in Cardiology</i> , 2017, 106, 711-721.	3.3	27
103	Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trials. <i>International Journal of Cardiology</i> , 2017, 244, 59-66.	1.7	21
104	Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 147-150.	3.0	17
105	Statins attenuate but do not eliminate the reverse epidemiology of total serum cholesterol in patients with non-ischemic chronic heart failure. <i>International Journal of Cardiology</i> , 2017, 238, 97-104.	1.7	5
106	2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 50.	0.6	280
107	Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. <i>Stroke</i> , 2017, 48, 3266-3273.	2.0	20
108	Heart rate prediction of outcome in heart failure following myocardial infarction depend on heart rhythm status an analysis from the high-risk myocardial infarction database initiative. <i>International Journal of Cardiology</i> , 2017, 249, 274-281.	1.7	1

#	ARTICLE	IF	CITATIONS
109	Myocardium at risk assessed by electrocardiographic scores and cardiovascular magnetic resonance - a MITOCARE substudy. Journal of Electrocardiology, 2017, 50, 725-731.	0.9	5
110	Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention. Data in Brief, 2017, 14, 197-205.	1.0	13
111	Administration of the Mitochondrial Permeability Transition Pore Inhibitor, TRO40303, prior to Primary Percutaneous Coronary Intervention, Does Not Affect the Levels of Pro-Inflammatory Cytokines or Acute-Phase Proteins. Cardiology, 2017, 138, 122-132.	1.4	6
112	Time-resolved tracking of the atrioventricular plane displacement in Cardiovascular Magnetic Resonance (CMR) images. BMC Medical Imaging, 2017, 17, 19.	2.7	35
113	Patient engagement. European Heart Journal, 2017, 38, 3114-3115.	2.2	13
114	European Heart Journal-Cardiovascular Pharmacotherapy in 2016: entering a new level of international recognition. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 3-4.	3.0	4
115	Neurohormonal Blockade in Heart Failure. Cardiac Failure Review, 2017, 03, 19.	3.0	53
116	Re: Antikoagulasjon og akronymer " NOAK eller DOAK?. Tidsskrift for Den Norske Lægeforening, 2017, 137, 424-424.	0.2	0
117	Sample Size in Clinical Cardioprotection Trials Using Myocardial Salvage Index, Infarct Size, or Biochemical Markers as Endpoint. Journal of the American Heart Association, 2016, 5, e002708.	3.7	31
118	Multi-vendor, multicentre comparison of contrast-enhanced SSFP and T2-STIR CMR for determining myocardium at risk in ST-elevation myocardial infarction. European Heart Journal Cardiovascular Imaging, 2016, 17, 744-753.	1.2	47
119	Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. European Journal of Heart Failure, 2016, 18, 482-489.	7.1	74
120	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.	2.2	5,689
121	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 2016, 18, 1609-1678.	1.7	3,523
122	Extent of Myocardium at Risk for Left Anterior Descending Artery, Right Coronary Artery, and Left Circumflex Artery Occlusion Depicted by Contrast-Enhanced Steady State Free Precession and T2-Weighted Short Tau Inversion Recovery Magnetic Resonance Imaging. Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	20
123	"Ten Commandments" of 2016 ESC Guidelines for the management of atrial fibrillation. European Heart Journal, 2016, 37, 2853-2853.	2.2	38
124	A new automatic algorithm for quantification of myocardial infarction imaged by late gadolinium enhancement cardiovascular magnetic resonance: experimental validation and comparison to expert delineations in multi-center, multi-vendor patient data. Journal of Cardiovascular Magnetic Resonance, 2016, 18, 27.	3.3	67
125	Automatic segmentation of myocardium at risk from contrast enhanced SSFP CMR: validation against expert readers and SPECT. BMC Medical Imaging, 2016, 16, 19.	2.7	11
126	Morphine in myocardial infarction: balancing on the tight rope. European Heart Journal, 2016, 37, 253-255.	2.2	7

#	ARTICLE	IF	CITATIONS
127	Non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a call for action. <i>Europace</i> , 2016, 18, 1-3.	1.7	44
128	Cost-effectiveness of antiplatelet drugs after percutaneous coronary intervention. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016, 2, 52-57.	4.0	4
129	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. <i>European Heart Journal</i> , 2016, 38, ehv643.	2.2	69
130	Assessment of Right Ventricular Afterload in COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 176-185.	1.6	5
131	Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. <i>European Heart Journal</i> , 2016, 37, 747-754.	2.2	62
132	Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 86-94.	3.0	59
133	End of story? Studies on prevention of reperfusion injury encounter perpetual defeats. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 46-47.	3.0	3
134	Expanding the Evidence Base. <i>American Journal of Therapeutics</i> , 2015, 22, e141-e150.	0.9	11
135	Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative. <i>European Journal of Heart Failure</i> , 2015, 17, 1144-1151.	7.1	84
136	Increased LV apical untwist during preload reduction in healthy humans: an echocardiographic speckle tracking study during lower body negative pressure. <i>Physiological Reports</i> , 2015, 3, e12330.	1.7	8
137	Cardiology update 2015: a tradition in excellent postgraduate education supported by the European Society of Cardiology * Sir Donald Ross, pioneer aortic valve surgeon * Plans of the British Cardiovascular Society to seek patients' views on research may aid research grant applications * Dr Hector Bueno reviews the proposed criteria of the German Society of Cardiology for the Establishment of Chest Pain Units 1 in the <i>European Heart Journal</i> 2015, 36, 1328-1333	2.2	0
138	Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. <i>European Heart Journal</i> , 2015, 36, ehv447.	2.2	35
139	The Effects of Climate Change on Cardiac Health. <i>Cardiology</i> , 2015, 131, 209-217.	1.4	1,123
140	Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2015, 169, 257-265.e1.	2.7	33
141	Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy. <i>Clinical Chemistry</i> , 2015, 61, 368-378.	3.2	37
142	Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. <i>Europace</i> , 2015, 17, 194-206.	1.7	41
143	Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. <i>Heart</i> , 2015, 101, 1475-1484.	2.9	13
144	Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 887-896.	3.9	20

#	ARTICLE	IF	CITATIONS
145	Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis. International Journal of Cardiology, 2015, 186, 104-105.	1.7	29
146	Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy. Circulation: Heart Failure, 2015, 8, 71-78.	3.9	238
147	ESC guidelines adherence is associated with improved survival in patients from the Norwegian Heart Failure Registry. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 31-36.	3.0	30
148	Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results. European Heart Journal, 2015, 36, 112-119.	2.2	154
149	Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. European Heart Journal, 2014, 35, 1864-1872.	2.2	303
150	Anticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decade. Fundamental and Clinical Pharmacology, 2014, 28, 353-363.	1.9	11
151	The association between meteorological events and acute heart failure: New insights from ASCEND-HF. International Journal of Cardiology, 2014, 177, 819-824.	1.7	9
152	Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction. Journal of the American College of Cardiology, 2014, 64, 2281-2293.	2.8	424
153	Effects of FX06 In Vitro on Platelet, Coagulation, and Fibrinolytic Biomarkers in Volunteers and Patients With Documented Coronary Artery Disease. American Journal of Therapeutics, 2014, 21, 91-98.	0.9	1
154	Effect of Aliskiren and Valsartan Combination Versus Aliskiren Monotherapy on Hemostatic Biomarkers in Hypertensive Diabetics. American Journal of Therapeutics, 2014, 21, 482-490.	0.9	0
155	Current role of neprilysin inhibitors in hypertension and heart failure. , 2014, 144, 41-49.		59
156	High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation. Circulation, 2014, 129, 625-634.	1.6	110
157	Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. European Heart Journal, 2014, 35, 2516-2523.	2.2	83
158	High-Sensitivity Troponin T and Risk Stratification in Patients With Atrial Fibrillation During Treatment With Apixaban or Warfarin. Journal of the American College of Cardiology, 2014, 63, 52-61.	2.8	133
159	A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace, 2014, 16, 308-319.	1.7	280
160	Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. European Heart Journal, 2014, 35, 224-232.	2.2	140
161	Obstructive sleep apnea: no independent association to troponins. Sleep and Breathing, 2014, 18, 351-358.	1.7	6
162	Prognostic Value of Microvascular Obstruction and Infarct Size, as Measured by CMR in STEMI Patients. JACC: Cardiovascular Imaging, 2014, 7, 930-939.	5.3	271

#	ARTICLE	IF	CITATIONS
163	Comorbidities and Polypharmacy. <i>Heart Failure Clinics</i> , 2014, 10, 367-372.	2.1	23
164	Myeloid-related protein-8/14 and C-reactive protein in individuals evaluated for obstructive sleep apnea. <i>Sleep Medicine</i> , 2014, 15, 762-768.	1.6	4
165	Fatal Sepsis and Systemic Inflammatory Response Syndrome After Off-Label Prasugrel. <i>American Journal of Therapeutics</i> , 2014, 21, e229-e233.	0.9	5
166	Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2013, 15, 456-464.	7.1	39
167	Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes. <i>International Journal of Cardiology</i> , 2013, 168, 2510-2517.	1.7	18
168	Pharmacological conversion of recent-onset atrial fibrillation: A systematic review. <i>Scandinavian Cardiovascular Journal</i> , 2013, 47, 2-10.	1.2	25
169	Oxygen therapy in acute coronary syndrome: are the benefits worth the risk?. <i>European Heart Journal</i> , 2013, 34, 1630-1635.	2.2	47
170	Renin-Angiotensin Blockade Combined With Natriuretic Peptide System Augmentation. <i>Circulation: Heart Failure</i> , 2013, 6, 594-605.	3.9	117
171	Cost Effectiveness of Drug-Eluting Stents as Compared With Bare Metal Stents in Patients With Coronary Artery Disease. <i>American Journal of Therapeutics</i> , 2013, 20, 596-601.	0.9	5
172	Prasugrel. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 253-254.	2.2	4
173	Effect of 1-year anti-TNF- α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. <i>American Journal of Hypertension</i> , 2012, 25, 644-650.	2.0	126
174	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012, 33, 2569-2619.	2.2	5,034
175	Increased heart rate variability during nondirective meditation. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 773-780.	1.8	45
176	Conclusion. <i>Advances in Cardiology</i> , 2012, 47, 165-165.	2.7	0
177	Introduction. <i>Advances in Cardiology</i> , 2012, 47, 1-4.	2.7	0
178	Regional $\langle LV \rangle$ deformation in healthy individuals during isovolumetric contraction and ejection phases assessed by 2D speckle tracking echocardiography. <i>Clinical Physiology and Functional Imaging</i> , 2012, 32, 372-379.	1.2	5
179	The l-arginine/asymmetric dimethylarginine ratio is improved by anti-Tumor Necrosis Factor- α therapy in inflammatory arthropathies. Associations with aortic stiffness. <i>Atherosclerosis</i> , 2012, 225, 160-165.	0.8	21
180	Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. <i>European Journal of Heart Failure</i> , 2012, 14, 1257-1264.	7.1	101

#	ARTICLE	IF	CITATIONS
181	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. <i>Europace</i> , 2012, 14, 1385-1413.	1.7	2,319
182	Third Universal Definition of Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1581-1598.	2.8	2,558
183	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. <i>European Heart Journal</i> , 2012, 33, 2719-2747.	2.2	3,144
184	Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials â€“ Common patterns in TRITON, RECORD, and PLATO?. <i>Thrombosis and Haemostasis</i> , 2012, 108, 412-414.	3.4	36
185	Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel. <i>Thrombosis and Haemostasis</i> , 2012, 107, 338-345.	3.4	29
186	Changes in diagnosing non-ST-segment elevation myocardial infarction after the introduction of a new high-sensitivity cardiac troponin T assay: a single-centre experience. <i>Clinical Laboratory</i> , 2012, 58, 1029-36.	0.5	3
187	Troponin I degradation in serum of patients with acute ischemic stroke. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2011, 71, 74-80.	1.2	4
188	Dronedarone in High-Risk Permanent Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 2268-2276.	27.0	547
189	Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2011, 365, 699-708.	27.0	918
190	Apixaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 981-992.	27.0	7,537
191	Gender differences among Norwegian patients with heart failure. <i>International Journal of Cardiology</i> , 2011, 146, 354-358.	1.7	24
192	Fatty Acid Binding Protein 4 Is Associated with Carotid Atherosclerosis and Outcome in Patients with Acute Ischemic Stroke. <i>PLoS ONE</i> , 2011, 6, e28785.	2.5	56
193	Corrigendum to: â€“Guidelines for the management of atrial fibrillationâ€™™ [European Heart Journal (2010) 31, 2369â€“2429 and EP-Europace (2010) 12, 1360â€“1420]. <i>European Heart Journal</i> , 2011, 32, 1172-1172.	2.2	133
194	Changes in arterial stiffness during continued infliximab treatment in patients with inflammatory arthropathies. <i>Fundamental and Clinical Pharmacology</i> , 2011, 25, 511-517.	1.9	23
195	Reduced preload elicits increased LV twist in healthy humans. <i>Clinical Physiology and Functional Imaging</i> , 2011, 31, 382-389.	1.2	14
196	Activated Leukocyte Cell Adhesion Molecule and Prognosis in Acute Ischemic Stroke. <i>Stroke</i> , 2011, 42, 2453-2458.	2.0	26
197	Relation of cardiac troponin I and microvascular obstruction following ST-elevation myocardial infarction. <i>Acute Cardiac Care</i> , 2011, 13, 48-51.	0.2	4
198	Early Prediction of Increased Arterial Stiffness in Patients with Chronic Inflammation: A 15-year Followup Study of 108 Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 606-612.	2.0	37

#	ARTICLE	IF	CITATIONS
199	Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. <i>European Heart Journal</i> , 2011, 32, 1854-1864.	2.2	343
200	Incremental value of a combination of cardiac troponin T, N-terminal pro-brain natriuretic peptide and C-reactive protein for prediction of mortality in end-stage renal disease. <i>Scandinavian Journal of Urology and Nephrology</i> , 2011, 45, 151-158.	1.4	14
201	Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 812-817.	0.9	101
202	Amyotrophic lateral sclerosis (ALS), a novel rare cause of elevated plasma troponin T levels. <i>Clinical Laboratory</i> , 2011, 57, 615-8.	0.5	8
203	Influence of ST-Segment Recovery on Infarct Size and Ejection Fraction in Patients With ST-Segment Elevation Myocardial Infarction Receiving Primary Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2010, 105, 1223-1228.	1.6	14
204	Optimal Time-Point of ST-Segment Assessment for Risk-Stratification Following Primary Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2010, 105, 1648-1649.	1.6	0
205	Editorial: Sudden cardiac death – the challenge to cardiology. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 535-537.	1.9	2
206	'Treat to target': moving targets from hypertension, hyperlipidaemia and diabetes to rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 629-630.	0.9	62
207	Tumor Necrosis Factor- α Antagonists Improve Aortic Stiffness in Patients With Inflammatory Arthropathies. <i>Hypertension</i> , 2010, 55, 333-338.	2.7	144
208	Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. <i>European Heart Journal</i> , 2010, 31, 227-235.	2.2	59
209	NT-proBNP predicts mortality in patients with rheumatoid arthritis: results from 10-year follow-up of the EURIDISS study. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1946-1950.	0.9	36
210	Corrigendum to –ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 [Eur Heart J 2008;29:2388-2442 and Eur J Heart Fail 2008;10:933-989]. <i>European Journal of Heart Failure</i> , 2010, 12, 416-416.	7.1	1
211	A window into your heart: taking cardiac troponin to the next level. <i>Biomarkers in Medicine</i> , 2010, 4, 889-894.	1.4	2
212	The PLATO trial: do you believe in magic?. <i>European Heart Journal</i> , 2010, 31, 764-767.	2.2	22
213	Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2010, 31, 2369-2429.	2.2	4,635
214	COPD Predicts Mortality in HF: The Norwegian Heart Failure Registry. <i>Journal of Cardiac Failure</i> , 2010, 16, 225-229.	1.7	65
215	Maximizing scientific knowledge from randomized clinical trials. <i>American Heart Journal</i> , 2010, 159, 937-943.	2.7	12
216	Impact of time to therapy and presence of collaterals on the efficacy of FX06 in acute ST elevation myocardial infarction: a substudy of the F.I.R.E., the Efficacy of FX06 in the prevention of myocardial reperfusion injury trial. <i>EuroIntervention</i> , 2010, 5, 946-952.	3.2	12

#	ARTICLE	IF	CITATIONS
217	Hotline sessions of the 30th European Congress of Cardiology. European Heart Journal, 2009, 30, 1151-1151.	2.2	0
218	Usefulness of Natriuretic Peptide Testing for Long-Term Risk Assessment Following Acute Ischemic Stroke. American Journal of Cardiology, 2009, 104, 287-291.	1.6	26
219	Relation of Cardiac Troponin I Measurements at 24 and 48 Hours to Magnetic Resonanceâ€Determined Infarct Size in Patients With ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2009, 104, 1472-1477.	1.6	54
220	Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis, 2009, 27, 48-56.	2.1	59
221	Antiplatelet â€resistanceâ€™™ and â€nonâ€™respondersâ€™™: what do these terms <i>really</i> mean?. Fundamental and Clinical Pharmacology, 2009, 23, 11-18.	1.9	7
222	Interpreting clinical trials: the â€Beautifulâ€™™ case. Fundamental and Clinical Pharmacology, 2009, 23, 261-262.	1.9	1
223	Association of platelet responsiveness with clopidogrel metabolism: Role of compliance in the assessment of â€resistanceâ€™. American Heart Journal, 2009, 158, 925-932.	2.7	64
224	Effect of Intravenous FX06 as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2009, 53, 720-729.	2.8	143
225	Androgenic Anabolic Steroid Abuse and the Cardiovascular System. Handbook of Experimental Pharmacology, 2009, , 411-457.	1.8	94
226	Clinical review: Impact of statin substitution policies on patient outcomes. Annals of Medicine, 2009, 41, 242-256.	3.8	24
227	Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease. Journal of Thrombosis and Thrombolysis, 2008, 25, 207-213.	2.1	30
228	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal, 2008, 29, 2388-2442.	2.2	2,656
229	Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129Â314 patients. Fundamental and Clinical Pharmacology, 2008, 22, 315-321.	1.9	57
230	Comparison of four different cardiac troponin assays in patients with end-stage renal disease on chronic haemodialysis. Acute Cardiac Care, 2008, 10, 173-180.	0.2	8
231	Telmisartan and Stroke Reduction in the ONTARGET Trial: Benefit beyond Blood Pressure Lowering?. Cerebrovascular Diseases, 2008, 26, 563-564.	1.7	0
232	Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting. Thrombosis and Haemostasis, 2008, 100, 314-8.	3.4	3
233	Antiplatelet Properties of Escitalopram in Patients with the Metabolic Syndrome: A Dose-Ranging In Vitro Study. Neuropsychopharmacology, 2007, 32, 2369-2374.	5.4	19
234	Cholesterol and peripheral vascular disease: A neglected topic?. Scandinavian Cardiovascular Journal, 2007, 41, 136-137.	1.2	1

#	ARTICLE	IF	CITATIONS
235	Rationale and Design of the F.I.R.E.™ Study. <i>Cardiology</i> , 2007, 108, 117-123.	1.4	16
236	Asymptomatic Myocardial Infarction prior to Ischemic Stroke?. <i>Cerebrovascular Diseases</i> , 2007, 24, 318-318.	1.7	1
237	Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12® rapid analyzer: The VERify Thrombosis risk ASsessment (VERITAS) study. <i>Thrombosis Research</i> , 2007, 119, 277-284.	1.7	198
238	Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: Hitting the TARGET in the TENACITY trial?. <i>Thrombosis Research</i> , 2007, 119, 175-181.	1.7	7
239	Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease. <i>American Heart Journal</i> , 2007, 153, 371-377.	2.7	9
240	European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) <i>TJ ETQq0 0 0 BT / Overlock 10 T</i>	2.2	2,331
241	FCP welcomes Cardiovascular Pharmacology and Drug Therapy. <i>Fundamental and Clinical Pharmacology</i> , 2007, 21, 457-457.	1.9	0
242	Frequency and Significance of Troponin T Elevation in Acute Ischemic Stroke. <i>American Journal of Cardiology</i> , 2007, 99, 108-112.	1.6	148
243	Assessment of Bleeding Events in Clinical Trials—Proposal of a New Classification. <i>American Journal of Cardiology</i> , 2007, 99, 288-290.	1.6	68
244	Mechanism of Troponin Elevations in Patients With Acute Ischemic Stroke. <i>American Journal of Cardiology</i> , 2007, 99, 867-870.	1.6	84
245	The relation between electrocardiographic ST-T changes and NT-proBNP in patients with acute ischemic stroke. <i>Scandinavian Cardiovascular Journal</i> , 2007, 41, 294-298.	1.2	7
246	Rheumatic mitral valve stenosis mimicking advanced lung cancer. <i>Heart and Vessels</i> , 2007, 22, 345-348.	1.2	2
247	Escitalopram, but Not Its Major Metabolites, Exhibits Antiplatelet Activity in Humans. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 172-177.	1.4	25
248	Dipyridamole Decreases Protease-Activated Receptor and Annexin-V Binding on Platelets of Poststroke Patients with Aspirin Nonresponsiveness. <i>Cerebrovascular Diseases</i> , 2006, 21, 98-105.	1.7	16
249	Time Course of Degradation of Cardiac Troponin I in Patients With Acute ST-Elevation Myocardial Infarction. <i>Circulation Research</i> , 2006, 99, 1141-1147.	4.5	47
250	Prevalence of diastolic dysfunction as a possible cause of dyspnea in the elderly. <i>American Journal of Medicine</i> , 2005, 118, 25-31.	1.5	31
251	Echocardiographic indices of left ventricular diastolic dysfunction in 647 individuals with preserved left ventricular systolic function. <i>European Journal of Heart Failure</i> , 2004, 6, 439-447.	7.1	16
252	How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?. <i>Journal of Cardiac Failure</i> , 2004, 10, 297-303.	1.7	110

#	ARTICLE	IF	CITATIONS
253	Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy. <i>Thrombosis Research</i> , 2004, 113, 197-204.	1.7	35
254	Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 563-567.	1.0	79
255	Aspirin inhibits surface glycoprotein IIb/IIIa, P-selectin, CD63, and CD107a receptor expression on human platelets. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 249-253.	1.0	40
256	Aggrenox [®] (Extended-Release Dipyridamole and Low-Dose Aspirin in Combination): Protecting Platelets from Excessive Activation in Patients with Vascular Events. <i>Cardiology</i> , 2002, 2, 93-104.	0.3	3
257	Effects of in vitro exposure of alcohol on surface receptor expression of human platelets. <i>Clinical Physiology and Functional Imaging</i> , 2002, 22, 153-156.	1.2	13
258	Selective Serotonin Reuptake Inhibitors: Future Treatment of Vascular Disease?. <i>Cardiology</i> , 2001, 1, 332-340.	0.3	2
259	Editors'™ Introductory Note. <i>Cardiology</i> , 2001, 1, 241-241.	0.3	0
260	Platelets and Thrombolysis: Cooperation or Contrariety?. <i>Cardiology</i> , 2001, 1, 281-290.	0.3	5
261	Biomarkers and Exercise Training: A Possible Missing Link between Physical Activity and Mortality Benefit in Patients with Heart Failure. <i>Cardiology</i> , 2001, 1, 110-124.	0.3	0
262	Welcome Address "from the Editors. <i>Cardiology</i> , 2001, 1, 1-1.	0.3	0
263	Cell Adhesion Molecules in Cardiovascular Pathology "A Glance into the Future?. <i>Cardiology</i> , 2001, 1, 225-235.	0.3	4
264	Effect of coronary thrombolysis on the plasma concentration of osteonectin (SPARC, BM40) in patients with acute myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 10, 197-202.	2.1	5
265	Lack of nuclear apoptosis in cardiomyocytes and increased endothelin-1 levels in a rat heart model of myocardial stunning. <i>Basic Research in Cardiology</i> , 2000, 95, 308-315.	5.9	16
266	Extensive Troponin I and T Modification Detected in Serum From Patients With Acute Myocardial Infarction. <i>Circulation</i> , 2000, 102, 1221-1226.	1.6	282
267	Atrioventricular plane motion during dobutamine-atropine stress echocardiography: The biphasic response in healthy subjects revisited. <i>Journal of the American Society of Echocardiography</i> , 2000, 13, 885-890.	2.8	6
268	Increased soluble platelet / endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy. <i>European Journal of Heart Failure</i> , 1999, 1, 243-249.	7.1	43
269	Excitation-Transcription Coupling Mediated by Zinc Influx through Voltage-dependent Calcium Channels. <i>Journal of Biological Chemistry</i> , 1995, 270, 2473-2477.	3.4	215
270	Relationship Between Intracellular Calcium and Contractile Force in Stunned Myocardium. <i>Circulation Research</i> , 1995, 76, 1036-1048.	4.5	174

#	ARTICLE	IF	CITATIONS
271	Magnesium deficiency prolongs myocardial stunning in an open-chest swine model. International Journal of Cardiology, 1994, 47, 105-115.	1.7	18
272	Effects of Magnesium Supplementation in a Porcine Model of Myocardial Ischemia and Reperfusion. Journal of Cardiovascular Pharmacology, 1994, 24, 603-611.	1.9	28